1. P1188: PERSONALIZED TREATMENT ACCORDING TO BIOLOGICAL PROFILE IMPROVES OUTCOME OF NEWLY DIAGNOSED PATIENTS AFFECTED BY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE EXPERIENCE. (23rd June 2022) Authors: Guidetti, A.; Pasquale, R.; Dodero, A.; Chiappella, A.; Devizzi, L.; Farina, L.; Rusconi, C.; Pennisi, M.; Corradini, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1074 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38). (17th June 2021) Authors: Pirosa, M. C.; Orsucci, L.; Feugier, P.; Tani, M.; Ghesquieres, Hervé; Musuraca, G.; Baldini, L.; Merli, F.; De Renzis, B.; Gyan, E.; Gini, G.; Marino, D.; Gressin, R.; Morschhauser, F.; Palombi, F.; Cavallo, F.; Conconi, A.; Le Gouill, S.; Tilly, Hervé; Zanni, M. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗